FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3028968856> ?p ?o ?g. }

• W3028968856 endingPage "398" @default.
• W3028968856 startingPage "395" @default.
• W3028968856 abstract "ObjectiveTo explore whether the prognostic efficiency of international prognostic index (IPI) can be further improved by interim 18F-fluorodeoxyglucose (FDG) PET/CT.MethodsA total of 185 patients (116 males, 69 females; average age 49 years) with pathologically confirmed diffuse large B-cell lymphoma (DLBCL) from January 2004 to January 2014 were enrolled in this retrospective study. The risk was classified by IPI (0-2 was considered as low risk, 3-5 was considered as high risk) and all patients underwent 18F-FDG PET/CT scan before and after 4 cycles of immunochemotherapy. Based on interim 18F-FDG PET/CT imaging, 5-point Deauville score was used to reclassify DLBCL patient into negative group and positive group, and the interpretations were evaluated for 2-year progression-free survival (PFS) and overall survival (OS) rates. Kaplan-Meier analysis, log-rank test and Cox regression were used for data analysis.ResultsWith a median follow-up of 27 (2-146) months, the 2-year PFS and OS rates were 60%(111/185) and 81%(150/185), respectively. A total of 114 patients were included in the low-risk group and 71 patients were in the high-risk group. Both 2-year PFS rates and OS rates between the 2 groups were statistically different: 72%(82/114) vs 37%(26/71), χ2=20.86, P<0.01; 90%(103/114) vs 63%(45/71), χ2=13.39, P<0.01. The interim PET/CT showed 113 patients with negative results and 72 patients with positive results, whose 2-year PFS rates and OS rates were also statistically different: 82%(93/113) vs 24%(17/72), χ2=66.66, P<0.01; 90%(102/113) vs 51%(37/72), χ2 =33.11, P<0.01. In the low-risk group, 85 patients were PET-negative and 29 patients were PET-positive. The 2-year PFS rates were 88%(75/85) and 31%(9/29), respectively (χ2=35.52, P<0.01). The 2-year OS rates were 96% (82/85) and 66%(19/29), respectively (χ2=11.88, P<0.01). In the high-risk group, 28 patients were PET-negative and 43 patients were PET-positive. The 2-year PFS and OS rates were 64%(18/28) vs 19%(8/43; χ2=17.33, P<0.01) and 86%(24/28) vs 49%(21/43; χ2=9.95, P<0.01), respectively.ConclusionsBoth IPI and interim 18F-FDG PET/CT have the prognostic value for patients with DLBCL. Interim 18F-FDG PET/CT can improve the prognostic efficiency of IPI.Key words: Lymphoma, large B-cell, diffuse; Drug therapy, combination; Prognosis; Positron-emission tomography; Tomography, X-ray computed; Deoxyglucose" @default.
• W3028968856 created "2020-06-05" @default.
• W3028968856 creator A5005612152 @default.
• W3028968856 creator A5029635712 @default.
• W3028968856 creator A5031540032 @default.
• W3028968856 creator A5045027028 @default.
• W3028968856 creator A5067011239 @default.
• W3028968856 creator A5087664088 @default.
• W3028968856 date "2018-06-25" @default.
• W3028968856 modified "2023-09-27" @default.
• W3028968856 title "Prognostic efficiency of interim 18F-FDG PET/CT in patients with diffuse large B-cell lymphoma" @default.
• W3028968856 doi "https://doi.org/10.3760/cma.j.issn.2095-2848.2018.06.004" @default.
• W3028968856 hasPublicationYear "2018" @default.
• W3028968856 type Work @default.
• W3028968856 sameAs 3028968856 @default.
• W3028968856 citedByCount "0" @default.
• W3028968856 crossrefType "journal-article" @default.
• W3028968856 hasAuthorship W3028968856A5005612152 @default.
• W3028968856 hasAuthorship W3028968856A5029635712 @default.
• W3028968856 hasAuthorship W3028968856A5031540032 @default.
• W3028968856 hasAuthorship W3028968856A5045027028 @default.
• W3028968856 hasAuthorship W3028968856A5067011239 @default.
• W3028968856 hasAuthorship W3028968856A5087664088 @default.
• W3028968856 hasConcept C126322002 @default.
• W3028968856 hasConcept C166957645 @default.
• W3028968856 hasConcept C167135981 @default.
• W3028968856 hasConcept C207103383 @default.
• W3028968856 hasConcept C2775842073 @default.
• W3028968856 hasConcept C2776957806 @default.
• W3028968856 hasConcept C2778476033 @default.
• W3028968856 hasConcept C2778559949 @default.
• W3028968856 hasConcept C2779338263 @default.
• W3028968856 hasConcept C2989005 @default.
• W3028968856 hasConcept C44249647 @default.
• W3028968856 hasConcept C50382708 @default.
• W3028968856 hasConcept C66339696 @default.
• W3028968856 hasConcept C71924100 @default.
• W3028968856 hasConcept C95457728 @default.
• W3028968856 hasConceptScore W3028968856C126322002 @default.
• W3028968856 hasConceptScore W3028968856C166957645 @default.
• W3028968856 hasConceptScore W3028968856C167135981 @default.
• W3028968856 hasConceptScore W3028968856C207103383 @default.
• W3028968856 hasConceptScore W3028968856C2775842073 @default.
• W3028968856 hasConceptScore W3028968856C2776957806 @default.
• W3028968856 hasConceptScore W3028968856C2778476033 @default.
• W3028968856 hasConceptScore W3028968856C2778559949 @default.
• W3028968856 hasConceptScore W3028968856C2779338263 @default.
• W3028968856 hasConceptScore W3028968856C2989005 @default.
• W3028968856 hasConceptScore W3028968856C44249647 @default.
• W3028968856 hasConceptScore W3028968856C50382708 @default.
• W3028968856 hasConceptScore W3028968856C66339696 @default.
• W3028968856 hasConceptScore W3028968856C71924100 @default.
• W3028968856 hasConceptScore W3028968856C95457728 @default.
• W3028968856 hasIssue "6" @default.
• W3028968856 hasLocation W30289688561 @default.
• W3028968856 hasOpenAccess W3028968856 @default.
• W3028968856 hasPrimaryLocation W30289688561 @default.
• W3028968856 hasVolume "38" @default.
• W3028968856 isParatext "false" @default.
• W3028968856 isRetracted "false" @default.
• W3028968856 magId "3028968856" @default.
• W3028968856 workType "article" @default.